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HGF-induced serine 897 phosphorylation of EphA2 regulates
epithelial morphogenesis of MDCK cells in 3D culture
Kohei Harada, Manabu Negishi and Hironori Katoh*
ABSTRACT
Expression of EphA2 is upregulated in various cancers that are
derived from epithelial cells and correlates with the ability of a cancer
cell to undergomigration and invasion. Here we have investigated the
role of EphA2 in the epithelial morphogenesis of Madin-Darby canine
kidney (MDCK) cells in three-dimensional culture. We show that
EphA2 is phosphorylated on serine residue 897 through hepatocyte
growth factor (HGF) stimulation using a phosphatidylinositol 3-kinase
(PI3K)–Akt-dependent mechanism and that this phosphorylation
is required for the formation of extensions, the first step of
tubulogenesis, in MDCK cysts. By contrast, stimulation using the
ligand ephrinA1 dephosphorylates EphA2 on serine residue 897 and
suppresses the HGF-induced morphological change. Furthermore,
activation of the small GTPase RhoG is involved in the HGF-induced
formation of extensions downstream of EphA2. These observations
suggest that a ligand-independent activity of EphA2 contributes to
epithelial morphogenesis.
KEY WORDS: EphA2, Epithelial–mesenchymal transition,
Rho family GTPases
INTRODUCTION
Ephrin (Eph)-family receptor tyrosine kinases play pivotal roles
in regulating cell migration and proliferation, and contribute to
many steps during development and in the maintenance of tissue
homeostasis through interactions with their ligand ephrins. Eph-
receptor–ephrin interactions induce the tyrosine kinase activity of
Eph receptors, and previous studies have shown that dysregulation
of Eph–ephrin interactions induces cancer progression (Pasquale,
2010; Boyd et al., 2014). Among Eph receptors, EphA2 is known as
a therapeutic target in cancers, because EphA2 is overexpressed in a
variety of human cancers and functions to promote cancer cell
migration and invasion. By contrast, stimulation of EphA2 with
ephrinA1 suppresses the malignant behavior of cancer cells,
indicating that EphA2 can have opposing roles in cancer cells in a
ligand-dependent and -independent manner. Recent studies suggest
that the oncogenic effects of EphA2 are attributed to its
phosphorylation on serine residue 897 (S897), which is mediated
by Akt activity downstream of growth factor receptor activation
(Miao, et al., 2009; Miao et al., 2015).
One of the most important families of downstream signaling
effectors in the Eph–ephrin system is the Rho-family of small
GTPases, which are well known as regulators of the actin
cytoskeleton in diverse cellular functions. Like other small
GTPases, Rho-family GTPases function as molecular switches by
cycling between a GDP-bound inactive form and a GTP-bound
active form. Following their activation, they interact with specific
effectors that lead to various biological functions. The activation
of Rho family GTPases requires GDP–GTP exchange, which is
catalyzed by various guanine nucleotide exchange factors (GEFs).
The Dbl family is one of the major classes of RhoGEFs that contain
tandem Dbl homology (DH) and pleckstrin homology (PH)
domains, mediating the GDP–GTP exchange through the DH
domain. The regulation of RhoGEFs in the Eph–ephrin system has
been extensively characterized in the nervous system (Egea and
Klein, 2007; Pitulescu and Adams, 2010), and it is known that
ephexin1 specifically binds to EphA receptors and induces
activation of Rho GTPases – including RhoA, Rac1 and Cdc42 –
to promote axon outgrowth. By contrast, ephrin stimulation induces
tyrosine phosphorylation of ephexin1, which enhances its exchange
activity toward RhoA, leading to axon retraction (Shamah et al.,
2001; Sahin et al., 2005). Furthermore, Vav-family RhoGEFs play
an important role in the regulation of ephrin-stimulated Eph-
receptor endocytosis, which is required for growth cone collapse
during axon guidance (Cowan et al., 2005). Other studies have also
implicated RhoGEFs that link Eph receptors to Rho GTPase
activation – including TIAM1, intersectins, kalirin and ephexin5 –
in the regulation of axon guidance and dendritic spine
morphogenesis (Irie and Yamaguchi, 2002; Penzes et al., 2003;
Tolias et al., 2007; Margolis et al., 2010).
EphA2 also regulates the activities of Rho-family small
GTPases in various cell types. For example, EphA2 activates
RhoA and destabilizes adherens junctions in response to ephrinA1
stimulation in mammary epithelial cells (Fang et al., 2008a).
EphA2-dependent RhoA activation is also involved in cell
migration and cell–cell repulsion in cancer cells (Fang et al.,
2005; Parri et al., 2007; Batson et al., 2014). The ephrin–EphA2-
dependent RhoA activation is mediated, at least in part, by Vav2
(Batson et al., 2014). However, ephrinA1 stimulation leads to RhoA
inactivation in Madin-Darby canine kidney (MDCK) cells through
p190RhoGAP (Wakayama et al., 2011). By contrast, stimulation of
EphA2 through ephrinA1 results in the recruitment of Vav-family
RhoGEFs to EphA2 and in activation of Rac1 to induce vascular
assembly and cell migration in endothelial cells (Brantley-Sieders
et al., 2004; Hunter et al., 2006); it also promotes invasion in
prostate cancer cells (Lin et al., 2012). The activation of Rac1 is also
required for ephrinA1-stimulated EphA2 endocytosis (Zhuang
et al., 2007; Boissier et al., 2013). We have previously identified
ephexin4 (also known as ARHGEF16) as a GEF for small GTPase
RhoG that interacts directly with EphA2 (Hiramoto-Yamaki
et al., 2010). Phosphorylation of S897 on EphA2 promotes the
recruitment of ephexin4 to EphA2 (Kawai et al., 2013; Akada et al.,
2014), and the EphA2–ephexin4 complex contributes to EphA2-
mediated cell migration and resistance to anoikis through the
activation of RhoG, independently of an interaction with ephrin
(Hiramoto-Yamaki et al., 2010; Harada et al., 2011). ActivatedReceived 24 September 2014; Accepted 20 March 2015
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RhoG recruits the ELMO–DOCK180 or ELMO–DOCK4 complex
to the plasma membrane and induces activation of Rac, which is
necessary for the promotion of cancer cell migration and invasion
(Katoh et al., 2006; Hiramoto et al., 2006). Activation of RhoG also
suppresses anoikis through a phosphatidylinositol 3-kinase (PI3K)–
Akt signaling pathway (Yamaki et al., 2007). These findings
provide a molecular link between phosphorylation of EphA2 on
S897 and tumor progression.
Most studies have highlighted the roles of EphA2 in cancer cells;
however, it is expressed in a wide range of epithelial tissues
(Lindberg and Hunter, 1990). A previous study has reported that
EphA2 is required for the development of mammary glands (Vaught
et al., 2009), although the molecular mechanism of EphA2-
mediated epithelial morphogenesis is poorly understood. Here, we
approach this issue by using three-dimensional (3D) cell culture of
MDCK cells, which is useful for investigating the formation of
epithelial structure. In this system, when MDCK cells are cultured
in Matrigel containing extracellular matrix (ECM) proteins, they
form cysts comprising a monolayer of polarized cells surrounding
a central lumen. In addition, following treatment of MDCK cysts
with hepatocyte growth factor (HGF), they initially undergo a
partial epithelial–mesenchymal transition (EMT) and produce actin-
rich extensions from their basal membrane, the first step of
tubulogenesis (O’Brien et al., 2002; Zegers et al., 2003). Our results
demonstrate that phosphorylation of EphA2 on S897 is required for
HGF-induced formation of extensions and that RhoG functions as a
key downstream regulator of EphA2 in HGF signaling. In a
previous study in which MDCK cells were cultured in collagen gel,
ephrinA1 stimulation was characterized as a negative regulator of
HGF-induced branching morphogenesis (Miao et al., 2003),
although its molecular mechanism remains to be determined. In
this study, we show that stimulation of EphA2 with ephrinA1 in
MDCK cysts causes dephosphorylation of EphA2 on S897 and
suppresses the formation of extensions that are induced by HGF.
RESULTS
Knockdown of EphA2 suppresses HGF-induced formation of
extensions in MDCK cysts
First, to examine the localization of EphA2 in MDCK cysts, we
performed immunofluorescence analyses. Cells that had been
grown in Matrigel for 10 days were stained with phalloidin (to
label F-actin and visualize cyst structure) an antibody against
EphA2, and they were imaged by using confocal microscopy.
EphA2 was localized mainly at the basal surface of cysts and weakly
detected at cell–cell contacts (Fig. 1A). To determine whether
EphA2 participates in the formation and maintenance of cysts, we
transfected MDCK cells with short hairpin RNA (shRNA) against
control luciferase (shControl) or canine EphA2 (shEphA2) and
established the control and EphA2-depleted cell lines (Fig. 1B).
These cells were grown in Matrigel for 10 days to form cysts and
then stained for F-actin. We confirmed knockdown of EphA2 in
MDCK cysts that had been grown in 3D culture for 10 days by
using immunoblotting (Fig. 1C) and immunofluorescence analysis
(Fig. 1D). EphA2-depleted cells developed into normal cysts with
a single lumen, and no significant difference was found in the
percentage of normal cysts between shEphA2-expressing cells and
untransfected or shControl-expressing cells (Fig. 1E,F), indicating
that EphA2 is dispensable for the formation and maintenance of
cysts. Next, we investigated the effect of EphA2 knock down on
tubulogenesis that had been induced though HGF stimulation.
WhenMDCK cysts are treated with HGF for 48 hours, they produce
one or more actin-rich extensions from their basal membrane
(O’Brien et al., 2002; Zegers et al., 2003; Fig. 1G, upper panels).
We quantified the cysts with extensions after treatment with HGF
and found a marked decrease in the percentage of cysts with
extensions formed from EphA2-depleted cells compared to
those formed from untransfected or control cells (Fig. 1G,H).
Collectively, these results suggest that EphA2 is required for the
formation of extensions in MDCK cysts in response to HGF
stimulation.
Phosphorylation of EphA2 on S897 is required for HGF-
induced formation of extensions in MDCK cysts
To investigate the mechanism of EphA2-mediated formation of
extensions, we used human wild-type EphA2 (EphA2-WT), which
was resistant to the shRNA against canine EphA2, and two human
EphA2 mutants, EphA2-SA and EphA2-KM (Fig. 2A). EphA2-SA
contains an alanine substitution at the S897 phosphorylation site
(Miao et al., 2009; Kawai et al., 2013), and EphA2-KM has
a mutation in the tyrosine kinase domain (K646M) that impairs its
tyrosine kinase activity (Wang et al., 2002). We introduced these
constructs into EphA2-depleted cells, and immunoblot analysis
showed similar expression levels of EphA2 in these cell lines and
the control cells when cultured in two dimensions (Fig. 2B) and
grown in Matrigel for 10 days (Fig. 2C). Also, the phosphorylation
status of EphA2 in these cell lines did not change (Fig. 2C). These
cell lines were treated with HGF for 48 hours after formation of
cysts. Expression of EphA2-WT or EphA2-KM restored HGF-
induced formation of extensions, whereas expression of EphA2-SA
failed to rescue the morphological defect caused by EphA2 knock
down (Fig. 2D,E). Taken together, these results suggest that
phosphorylation of S897 of EphA2, but not its tyrosine kinase
activity, is required for HGF-induced formation of extensions in
MDCK cysts.
EphA2 is phosphorylated on S897 through HGF and
dephosphorylated through ephrinA1 in MDCK cysts
To determine whether HGF stimulation induces phosphorylation of
EphA2 on S897 inMDCK cysts, lysates were prepared from cysts that
had been treated with or without HGF and then analyzed by
immunoblotting with an antibody against phosphorylated EphA2 at
S897 (pS897-EphA2). Stimulation of MDCK cysts with HGF
significantly enhanced the level of phosphorylation at S897 of EphA2
(Fig. 3A). EphA2 serves as a substrate of Akt downstream of growth
factor receptors and promotes cell migration and invasion in glioma
(Miao et al., 2009). Based on that study, we speculated that the
activation of PI3K–Akt signaling is involved in the HGF-induced
phosphorylation of EphA2 on S897 in MDCK cysts. We treated the
cysts with LY294002 (a PI3K-specific inhibitor) or MK-2206
(an Akt-specific inhibitor) and found that both of these inhibitors
completely suppressed HGF-induced phosphorylation of EphA2
on S897 in MDCK cysts (Fig. 3A). These results suggest that
HGF induces phosphorylation at S897 of EphA2 through a PI3K–
Akt-dependent signaling pathway. LY294002 also suppressed the
HGF-induced formation of extensions (Fig. 3B,C). Next, we
examined the distribution of EphA2 that was phosphorylated at
S897 inHGF-stimulated cysts by using immunofluorescence analysis
with an antibody against pS897-EphA2, and pS897-EphA2 was
observed to be localized in actin-rich areas at the tip of extensions
(Fig. 3D).
A previous study has reported that ephrinA1 stimulation
suppresses HGF-induced cell protrusions in MDCK cells in
collagen gel (Miao et al., 2003). In agreement with this, we
observed that treatment with ephrinA1 significantly blocked the
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formation of extensions upon stimulation with HGF (Fig. 4A,B).
To determine whether ephrinA1 stimulation alters the level of
phosphorylation of EphA2 at S897, we analyzed lysates of cysts that
had been co-treated with HGF and ephrinA1 by immunoblotting
with antibodies against EphA2 and pS897-EphA2. Treatment
with ephrinA1 abolished HGF-induced upregulation of pS897-
EphA2 (Fig. 4C). Collectively, these results suggest that ephrinA1
negatively regulates HGF-induced formation of extensions in
MDCK cysts through dephosphorylation of EphA2 at S897. We
also examined phosphorylation of EphA2 at tyrosine residue 588
(Y588) in MDCK cysts. Y588 is located in the juxtamembrane
region of EphA2, and phosphorylation of this tyrosine residue is
required for tyrosine kinase activation of Eph receptors by ligand
ephrins (Kullander and Klein, 2002; Fang et al., 2008b). Although
stimulation with ephrinA1 enhanced the level of phosphorylation of
EphA2 at Y588, stimulation with HGF had no effect on the
phosphorylation of endogenous EphA2 (Fig. 4C) or EphA2-WT
and EphA2-KM at Y588 in EphA2-depleted MDCK cysts
(Fig. 4D). These results further support our conclusion that the
tyrosine kinase activity of EphA2 is dispensable for the
HGF-induced formation of extensions in MDCK cysts.
Ephexin4 mediates HGF-induced formation of extensions
through the activation of RhoG
We have previously revealed that phosphorylation of EphA2 at
S897 regulates the interaction with ephexin4 and RhoG activation
(Hiramoto-Yamaki et al., 2010; Kawai et al., 2013). To determine
whether ephexin4 is a candidate downstream effector of EphA2 in
HGF-stimulated MDCK cysts, we established an MDCK cell line
that expressed shRNA against canine ephexin4 (shEphexin4),
which effectively reduced the amount of endogenous ephexin4 in
MDCK cysts (Fig. 5A). Depletion of ephexin4 did not noticeably
Fig. 1. Knockdown of EphA2 suppresses HGF-
induced formation of extensions in MDCK cysts.
(A) MDCK cells were grown in Matrigel for 10 days, then
they were fixed and stained with an antibody against
EphA2 antibody (green) and phalloidin (red, labeling for
F-actin to visualize cyst structure). (B) Cell lysates from
MDCK cells expressing a control shRNA against
luciferase (shControl) or an shRNA against EphA2
(shEphA2) were analyzed by immunoblotting with
antibodies against EphA2 and α-tubulin. (C) MDCK cells
were grown in Matrigel for 10 days, and the cyst lysates
were analyzed by immunoblotting with antibodies against
EphA2 and α-tubulin. (D) MDCK cells expressing
shControl or shEphA2 were grown in Matrigel for 10 days
and then fixed. Cysts were stained with an antibody
against EphA2 (green) and phalloidin (red). (E) MDCK
cysts were stained with phalloidin. (F) Quantification
of the percentage of normal cysts. Data are the
means±s.e.m. from three independent experiments
(ns, not significant; one-way ANOVA with Dunnett T3).
(G) MDCK cells expressing shControl or shEphA2
were grown in Matrigel for 8 days, followed by treatment
with 50 ng/ml HGF for 48 hours. Cysts were stained with
phalloidin. Low mag., low magnification. (H)
Quantification of cysts with one or more actin-rich
extensions. Data are the means±s.e.m. of three
independent experiments (*P<0.05; ns, not significant;
one-way ANOVA with Dunnett T3). At least 100 cysts
were counted for each experiment. Scale bars: 50 µm.
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affect the ability to form proper cyst structure (Fig. 5B, left panels;
Fig. 5C). Next, we investigated the effect of knocking down
ephexin4 on HGF-induced epithelial morphogenesis in MDCK
cysts and observed a significant reduction in the percentage of
cysts with extensions in ephexin4-depleted cysts relative to that in
the control cysts (Fig. 5B, middle and right panels; Fig. 5D).
We performed rescue experiments with Flag-tagged wild-type
human ephexin4 (Flag-Ephexin4-WT) and an ephexin4 mutant
containing E291A and N466A substitutions [Flag-Ephexin4-AA,
analogous residues are required for the exchange activity of the
RhoG activator SGEF (Ellerbroek et al., 2004; Fig. 5E)]. The
RhoG activity in HEK293T cells that had been transfected with
Flag-Ephexin4-WT or Flag-Ephexin4-AAwas measured by using
a pulldown assay with the GST-fused N-terminal RhoG-binding
region of ELMO2 (GST-ELMO-NT), which could specifically
interact with the active form of RhoG (Katoh and Negishi, 2003;
Hiramoto-Yamaki et al., 2010), and Ephexin4-AA failed to
activate RhoG (supplementary material Fig. S1). In MDCK
cysts, the expression of Flag-Ephexin4-WT completely rescued
the defect in the formation of extensions caused by knock down of
ephexin4, whereas expression of Flag-Ephexin4-AA did not
(Fig. 5F,G). Taken together, these results suggest that ephexin4-
mediated RhoG activation is required for the HGF-induced
formation of extensions.
EphA2 mediates the activation of RhoG downstream of HGF
signaling
To confirm that HGF induces RhoG activation downstream of
EphA2, we measured RhoG activity in the control and EphA2-
depleted MDCK cells. In the control cells, stimulation with HGF
significantly enhanced the level of active RhoG, whereas it had little
effect on the level of active RhoG in EphA2-depleted cells
Fig. 2. Phosphorylation of EphA2 on S897
is required for HGF-induced formation of
extensions in MDCK cysts. (A) The EphA2
constructs used in this study. TM,
transmembrane; KD, kinase domain; SAM,
sterile-α-motif. Numbers indicate amino acid
position within the sequence. (B) Lysates
from MDCK cells expressing the indicated
shRNAs or co-expressing the EphA2
constructs (-WT, -SA or -KM) were analyzed
by immunoblotting with antibodies against
EphA2 and α-tubulin. (C) MDCK cells were
grown in Matrigel for 10 days, and the cyst
lysates were analyzed by immunoblotting
with antibodies against EphA2, EphA2
phosphorylated at S897 (pS897-EphA2) or
at Y588 (pY588-EphA2) and α-tubulin.
(D) MDCK cysts expressing the indicated
plasmids were treated with HGF for 48 hours
and then fixed. Cysts were stained with
phalloidin. Low mag., low magnification.
(E) Quantification of cysts with one or
more actin-rich extensions. Data are the
means±s.e.m. of four independent
experiments (*P<0.05; **P<0.01; ns, not
significant; one-way ANOVA with Dunnett
T3), and at least 100 cysts were counted for
each experiment. Scale bars: 50 µm.
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(Fig. 6A). Expression of EphA2-WT in EphA2-depleted cells
restored the activation of RhoG upon stimulation with HGF,
whereas expression of EphA2-SA did not (Fig. 6B). These results
suggest that EphA2 mediates HGF-induced RhoG activation
through phosphorylation at S897.
Next, we examined whether the expression of a constitutively
active form of RhoG (RhoG-V12) could override the effect of
EphA2 knock down on HGF-induced formation of extensions. We
introduced green fluorescent protein (GFP)-tagged RhoG-V12 into
EphA2-depleted cells, grew the cells in Matrigel and treated them
with HGF for 48 hours. Although expression of RhoG-V12 had
little effect on the formation of cysts, it could restore HGF-induced
formation of extensions from EphA2-depleted cells (Fig. 6C,D),
suggesting that RhoG activation is required downstream of EphA2
in HGF-induced formation of extensions.
DISCUSSION
EphA2, a member of the Eph-family receptor tyrosine kinases, is
widely expressed in epithelial cells, but its functional roles and the
molecular mechanisms remain incompletely understood. In this
study, we show that EphA2 is required for the formation of
extensions, the first step of HGF-induced remodeling into tubules in
MDCK cysts. In addition, phosphorylation of EphA2 on S897
induced by HGF through PI3K and Akt is essential for this
morphological change. Indeed, the PI3K inhibitor LY294002
inhibits the formation of extensions. By contrast, stimulation with
ephrinA1 dephosphorylates EphA2 on S897 and negatively
regulates HGF-induced formation of extensions. EphA2 is known
to be a substrate of Akt (Miao et al., 2009; Kawai et al., 2013), and
pS897-EphA2 and the products of PI3K, which activate Akt, show a
similar localization at the leading edge of cellular extensions in the
Fig. 3. EphA2 is phosphorylated on S897 throughHGF in
MDCK cysts. (A) MDCK cells were grown in Matrigel for
8 days and then treated with HGF for 48 hours in the
presence or the absence of 20 µM LY294002 or 1 µM MK-
2206. The cyst lysates were analyzed by immunoblotting
with antibodies against EphA2, pS897-EphA2 and α-tubulin.
The relative amount of pS897-EphA2 was determined by the
amount of pS897-EphA2 normalized to the amount of total
EphA2 in cyst lysates, analyzed by using ImageJ software.
Data are presented as the means±s.e.m. from four
independent experiments (*P<0.05; **P<0.01; one-way
ANOVA with Dunnett T3). (B) MDCK cells were grown in
Matrigel for 8 days, followed by treatment with HGF for 48
hour in the presence and the absence of 20 µM LY294002.
Low mag., low magnification. (C) Quantification of cysts
with one or more actin-rich extensions. Data are the
means±s.e.m. of four independent experiments
(***P<0.001; Student’s t-test), and at least 100 cysts were
counted for each experiment. (D) Following treatment with
HGF for 48 hours, MDCK cysts were stained with phalloidin
(red) and antibodies against pS897-EphA2 or EphA2
(green). Scale bars: 50 µm.
1916













cysts (Yu et al., 2003), supporting the idea that HGF stimulation
induces the activation of the PI3K–Akt signaling pathway followed
by Akt-mediated phosphorylation of EphA2 on S897, leading to the
formation of extensions in MDCK cysts. We also found that
ephexin4, which is recruited to pS897-EphA2 (Kawai et al., 2013),
serves as a RhoG activator and mediates HGF-induced formation of
extensions. By contrast, EphA2 and ephexin4 are not involved in the
formation and maintenance of MDCK cysts. Taken together, our
results suggest that the EphA2 and ephexin4 signaling pathway
is dispensable for the acquisition of apico-basal polarity but that
it plays an important role in the formation of extensions, an initial
step that is required for the formation of tubular structures
during epithelial morphogenesis. However, we cannot rule out the
possibility that ephexin4 regulates the HGF-induced morphological
change in parallel with EphA2 signaling. We tried to examine the
localization of ephexin4 in MDCK cysts, but we could not obtain
clear images of the location of ephexin4. The reason for this is
probably that our antibody against ephexin4 was not suitable for
immunofluorescence staining of the endogenous protein (Hiramoto-
Yamaki et al., 2010). We show here that the expression of a
constitutively active form of RhoG can restore HGF-induced
formation of extensions from EphA2-depleted cells. In addition,
phosphorylation of EphA2 at S897 is required for HGF-induced
RhoG activation. Therefore, these findings indicate that RhoG
activation is required for HGF-induced formation of extensions
downstream of EphA2 in MDCK cells. However, it is currently
unknown whether phosphorylation of EphA2 at S897 alone is
sufficient to produce actin-rich extensions in MDCK cysts
independently of HGF. The first paper concerning phosphorylation
of EphA2 at S897 has reported that a phosphomimetic mutation
(S897D) of EphA2 has the same effects as an S897A mutation. Both
S897AandS897Dmutations completelyabolish thepromotion of cell
migration by EphA2 (Miao et al., 2009). Therefore, it is possible that
S897-phosphomimetic mutants of EphA2 also fail to act as EphA2
that is phosphorylated at S897 inMDCK cysts. In this study, we show
that expression of constitutively active RhoG alone failed to produce
actin-rich extensions in the absence of HGF. Thus, our results suggest
that the EphA2–RhoG signaling pathway is necessary but not
sufficient for HGF-induced formation of extensions in MDCK cysts.
Our observations indicate that EphA2 is phosphorylated on S897
and promotes the formation of extensions in MDCK cysts
downstream of HGF in a ligand-independent manner. By contrast,
stimulation with the ligand ephrinA1 negates the effects of HGF on
the formation of extensions in MDCK cysts, consistent with a
previous report (Miao et al., 2003). Our results also demonstrate
that stimulation with ephrinA1 results in the dephosphorylation
of EphA2 on S897. These results suggest that EphA2 contributes
to the remodeling of epithelia during development through ligand-
dependent and -independent mechanisms, and that the ligand
ephrinA1 functions as a negative regulator of EphA2 ligand-
Fig. 4. EphrinA1 dephosphorylates EphA2 on
S897 and suppresses extension formation in
MDCK cysts. (A) MDCK cells grown in Matrigel were
treated with 1 µg/ml ephrinA1 for 24 hours in the
presence of HGF and then stained with phalloidin.
Low mag., low magnification. Scale bars: 50 µm.
(B) Quantification of cysts with one or more actin-rich
extensions. Data are the means±s.e.m. of three
independent experiments (***P<0.001; Student’s
t-test), and at least 100 cysts in randomly selected
fields were counted in one experiment. (C) MDCK
cysts were treated with 1 µg/ml ephrinA1 for 24 hours
in the presence of HGF. The cyst lysates were
analyzed by immunoblotting with antibodies against
EphA2, EphA2 phosphorylated at S897 (pS897-
EphA2) or at Y588 (pY588-EphA2) and α-tubulin. The
relative levels of pS897-EphA2 and pY588-EphA2
were determined by the amount of pS897-EphA2 or
pY588-EphA2 normalized to the amount of total
EphA2 in cyst lysates, as analyzed by using ImageJ
software. Data are presented as the means±s.e.m.
from four independent experiments (*P<0.05; ns, not
significant; one-way ANOVA with Dunnett T3).
(D) MDCK cells expressing the indicated plasmids
were grown in Matrigel for 8 days and then treated with
HGF for 48 hours. The cyst lysates were analyzed by
immunoblotting with antibodies against EphA2,
pY588-EphA2 and α-tubulin.
1917













independent signaling. Miao et al. have also demonstrated that
stimulation with ephrinA1 causes the retraction of preexisting cell
protrusions that had been induced by HGF in MDCK cells cultured
in collagen gel (Miao et al., 2003). In this study, we stimulated
MDCK cysts with HGF and ephrinA1 for the same period of time
(after 24 hours of treatment with HGF, cells were stimulated with
ephrinA1 and cultured for an additional 24 hours), and found that
stimulation with ephrinA1 caused dephosphorylation of EphA2 at
S897 and suppressed the formation of extensions that were induced
by HGF in our culture model. Therefore, it is possible that
dephosphorylation of EphA2 at S897 is sufficient to retract
preexisting extensions in MDCK cysts. We would like to use an
inducible EphA2-S897A mutant or EphA2 knockdown to address
this issue in future studies.
RhoG functions as a key upstream regulator of Rac1 (Katoh et al.,
2000; Hiramoto-Yamaki et al., 2010). In MDCK cells, treatment
with HGF stimulates Rac1 activity and induces phosphorylation
of a downstream Rac1 effector, PAK, both of which are suppressed
upon stimulation with ephrinA1 (Miao et al., 2003). In addition,
inactivation of Rac1 inhibits HGF-induced formation of extensions
(Miao et al., 2003; Yagi et al., 2012b). Therefore, RhoG might
contribute to extension formation in HGF-stimulated MDCK
cysts by regulating Rac1 activity at the basal membrane,
downstream of EphA2 and ephexin4. By contrast, inactivation of
RhoA or its downstream effector ROCK enhances HGF-induced
formation of extensions and attenuates the inhibitory effect of
ephrinA1 (Miao et al., 2003; Yu et al., 2003). Further studies are
needed to elucidate whether phosphorylation of EphA2 at S897
mediates the formation of extensions in MDCK cysts by regulating
Rac1 and/or RhoA activity.
EphA2 is overexpressed in a variety of human cancers (Pasquale,
2010; Boyd et al., 2014), and a correlation between the level of
Fig. 5. Ephexin4mediatesHGF-induced formation
of extensions through the activation of RhoG.
(A) Lysates fromMDCK cysts expressing shControl or
the shRNA against ephexin4 (shEphexin4) that had
been grown for 10 days were analyzed by
immunoblotting with antibodies against ephexin4 and
α-tubulin. (B) MDCK cysts expressing shControl or
shEphexin4 were cultured in the presence or absence
of HGF. Then they were stained with phalloidin.
(C) Quantification of the percentage of normal cysts.
Data are the means±s.e.m. of three independent
experiments (ns, not significant; Student’s t-test).
(D Quantification of cysts with one or more actin-rich
extensions. Data are the means±s.e.m. of three
independent experiments (*P<0.05; Student’s t-test).
At least 100 cysts were counted for each experiment.
(E) The ephexin4 constructs used in this study.
DH, Dbl homology domain; PH, pleckstrin homology
domain; SH3, Src homology domain 3. Numbers
indicate amino acid position within the sequence.
(F) MDCK cells expressing the indicated shRNAs or
co-expressing the Flag-tagged ephexin4 constructs
(-WT or -AA) were treated with HGF for 48 hours and
stainedwith phalloidin. (G) Quantification of cysts with
one or more actin-rich extensions. Data are the
means±s.e.m. of five independent experiments
(**P<0.01; ns, not significant; one-way ANOVA with
Dunnett T3), and at least 100 cysts were counted for
each experiment. Low mag., low magnification. Scale
bars: 50 µm.
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phosphorylation of EphA2 at S897 and malignant progression has
been reported (Miao et al., 2009). Thus, these findings suggest that
the spatial and temporal regulation of phosphorylation at S897 could
be important for the formation andmaintenance of epithelial tissues.
MATERIALS AND METHODS
Plasmids and antibodies
The expression plasmids encoding human EphA2 and Flag-tagged human
ephexin4 were obtained, as described previously (Hiramoto-Yamaki et al.,
2010), and subcloned into pcDNA3 vector (Life Technologies). EphA2-
SA (S897A) was constructed as described previously (Kawai et al., 2013).
EphA2-KM (K646M) and Ephexin4-AA (E291A/N466A) were
constructed by using PCR-mediated mutagenesis and subcloned into
pcDNA3 vector. Myc-tagged human RhoG was generated as described
previously (Katoh et al., 2000). EphA2 and Ephexin4 shRNAs were
designed to target 21 nucleotides of the canine EphA2 transcript (5′-
GGAGGGTGTCGTCTCCAAATA-3′) and the canine ephexin4 transcript
(5′-GCTACCTATTTCTGTTCAATG-3′). The targets of each transcript
were designed with no substantial identity to any mammalian gene
sequence and were expressed by using an shRNA expression vector,
pSilencer-hygro (Life Technologies). Control shRNA was designed to
target 19 nucleotides of luciferase, as described previously (Harada et al.,
2011).
The following antibodies were used in this study: a mouse monoclonal
antibody against Myc, a rabbit polyclonal antibody against EphA2 (C-20),
and a rat monoclonal antibody against RhoG (1F3 B3 E5) (Santa Cruz
Biotechnology); mouse monoclonal antibodies against Flag (M2) and α-
tubulin (Sigma); a rabbit polyclonal antibody against phosphorylated
EphA2 (at residue S897) (Cell Applications); rabbit monoclonal
antibodies against phosphorylated EphA2 (at residue S897; clone
D9A1) and phosphorylated EphA2 (at residue Y588; clone D7X2L,
Cell Signaling); a mouse polyclonal antibody against EphA2 (D7,
Millipore); secondary antibodies conjugated to horseradish peroxidase
(DAKO); and secondary antibodies conjugated to Alexa Fluor 488
(Invitrogen). F-actin was visualized with Rhodamine–phalloidin
Fig. 6. EphA2 mediates HGF-induced RhoG
activation. (A,B) MDCK cells expressing the
indicated plasmids were treated with 50 ng/ml
HGF for 1 minute at room temperature. Cell
lysates were incubated with GST-ELMO-NT, and
bound endogenous RhoG and total cell lysates
were analyzed using antibodies against RhoG
and EphA2. Relative RhoG activity was
determined by the amount of RhoG bound to
GST-ELMO-NT normalized to the amount of
RhoG in cell lysates, as analyzed by using
ImageJ software. Data are presented as the
means±s.e.m. from three or four independent
experiments (*P<0.05; one-way ANOVA with
Dunnett T3). (C) MDCK cells expressing
shEphA2 or co-expressing GFP-tagged RhoG-
V12 were treated with HGF for 48 hours and
stained using phalloidin. Low mag., low
magnification. (D) Quantification of cysts with
one or more actin-rich extensions. Data were the
means±s.e.m. of three independent experiments
(*P<0.05; ns, not significant; one-way ANOVA
with Dunnett T3), and at least 100 cysts were
counted for each experiment. Scale bars: 50 µm.
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(Invitrogen). The antibody against ephexin4 has been described
previously (Hiramoto-Yamaki et al., 2010).
Cell culture and transfection
MDCK cells were a gift from Etsuko Kiyokawa (Kanazawa Medical
University, Ishikawa, Japan). HEK293T and MDCK cells were grown in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum,
4 mM glutamine, 100 units/ml of penicillin and 0.1 mg/ml of streptomycin
under humidified air containing 5% CO2 at 37°C. Cells were transfected
with indicated expression vectors using Lipofectamine Plus (for HEK293T
cells) or Lipofectamine 2000 (for MDCK cells) (Life Technologies)
according to the manufacturer’s instructions. In some experiments, MDCK
cells were used after selection with 400 µg/ml of hygromycin-B or 500 µg/
ml of G418.
Formation of cysts and extensions
Cyst and cyst extension formation were performed as previously described
(Pollack et al., 1998; Martin-Belmonte et al., 2007; Yagi et al., 2012a). To
form cysts, MDCK cells were plated at a density of 7.5×103 cells onto
13-mm-diameter coverslips coated with 20 µl of growth-factor-reduced
Matrigel (BD Biosciences) in 24-well plates and cultured in medium
containing 2% growth-factor-reduced Matrigel for 10 days. For cyst
extension formation, MDCK cysts were grown in Matrigel for 8 days and
treated for 48 hours with 50 ng/ml HGF (R&D Systems) in medium
containing 2% growth-factor-reduced Matrigel. In some experiments, cysts
were treated with 1 µg/ml control-Fc or ephrinA1-Fc (R&D Systems) for
24 hours. The percentage of cysts with extensions was calculated by
counting the number of cysts with one or more actin-rich extensions
protruding from their basal surface, according to the quantification method
described previously (Eastburn et al., 2012).
Immunoblotting
To detect the level of phosphorylation of EphA2 at S897 in MDCK cysts,
cysts on Matrigel were incubated in 1.25 mM EDTA in PBS on ice for
1 hour to depolymerize Matrigel and then centrifuged for 5 minutes at
1500 g. After cysts had been washed twice with PBS, proteins were eluted
in Laemmli sample buffer. Proteins were separated by using SDS-PAGE,
and were transferred onto a polyvinylidene difluoride membrane
(Millipore Corporation) using electrophoresis. The membrane was
blocked with 3% low fat milk in Tris-buffered saline and then incubated
with primary antibodies. The primary antibodies were detected with
horseradish-peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence (ECL) detection kit (ECL Prime, GE Healthcare;
Chemi-Lumi one, Nacalai Tesque). To examine the involvement of the
PI3K–Akt pathway, cysts were treated with 20 µM LY294002 (a PI3K-
specific inhibitor, Calbiochem) or 1 µM MK-2206 (an Akt-specific
inhibitor, ChemieTek).
Measurement of RhoG activity
Measurement of RhoG activity in cells was performed as described
previously (Katoh and Negishi, 2003). The N-terminal RhoG-binding
domain of ELMO2 (ELMO-NT, amino acids 1–362) was expressed in
Escherichia coli as a fusion protein with GST and purified on glutathione–
Sepharose beads. The purified protein was suspended with 10 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 2 mM MgCl2 and 0.1 mM DTT and stored at
−80°C. Protein concentration was determined by comparing with BSA
standards after SDS-PAGE and by staining with Coomassie Brilliant Blue.
To determine RhoG activity in MDCK cells, cells were serum-starved and
then treated with 50 ng/ml HGF for 1 minute at room temperature. The cells
were lysed with the ice-cold cell lysis buffer (10 mM Tris–HCl, pH 7.5,
100 mMNaCl, 2 mMMgCl2, 1% Nonidet P-40, 10% glycerol, 1 mM DTT,
1 mMPMSF, 10 μg/ml Aprotinin and 10 μg/ml Leupeptin) containing 20 μg
of GST-ELMO-NT. Cell lysates were then centrifuged for 5 minutes at
10,000 g at 4°C, and the supernatants were incubated with glutathione–
Sepharose beads for 30 minutes at 4°C. The beads were washed with the
lysis buffer, and bound proteins were analyzed by using SDS-PAGE and
immunoblotting.
Immunofluorescence microscopy
Cysts on Matrigel-coated coverslips were fixed with 4% paraformaldehyde
in PBS for 30 minutes at room temperature and washed twice with PBS.
After residual paraformaldehyde had been quenched with 50 mM NH4Cl
in PBS, cysts were permeabilized with 0.5% Triton X-100 in PBS for
10 minutes and incubated with 10% goat serum in PBS for 30 minutes to
block nonspecific antibody binding. Then cysts were incubated with
primary antibodies in Can Get Signal Immunostain Immunoreaction
Enhancer Solution A (TOYOBO) overnight at 4°C. After washing with
PBS, cells were incubated with Rhodamine–phalloidin and a secondary
antibody conjugated with Alexa Fluor 488 for 2 hours, washed with PBS for
30 minutes and mounted upside down on glass-bottomed dishes in 90%
glycerol containing 0.1% p-phenylenediamine dihydrochloride in PBS.
To visualize cyst structure, cysts were incubated with 10% FBS in PBS for
30 minutes and incubated with Rhodamine–phalloidin in blocking buffer
for 2 hours. Images were acquired using a laser-scanning confocal imaging
system (EZ-C1 version 3.20 software; Nikon) and a microscope (Eclipse
TE2000-U; Nikon) with a 60×/NA 1.40 oil objective (Nikon) and a digital
camera (DXM1200C; Nikon). All images were prepared using Photoshop
(Adobe).
Data analysis
Statistical significance was established using the two-sample Student’s t-test
or the analysis of variance (ANOVA) and post-hoc test (Dunnett T3) (SPSS
software version 16.0, IBM). P<0.05 was considered significant.
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Fig. S1. Effect of Ephxein4-WT or Ephexin4-AA expression on RhoG activity. HEK293T cells were co-transfected with Myc-tagged 
RhoG and Flag-tagged Ephexin4 (-WT or -AA). Cell lysates were incubated with GST-ELMO-NT, and bound Myc-tagged RhoG and 
total cell lysates were analyzed with antibodies against RhoG and Flag.
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